Clinical Obesity and New‐Onset Atrial Fibrillation: A Population‐Based Cohort Study From the Kailuan Cohort
Main finding · New-onset AFResult — go to the resultHazard ratio 1.29 95% CI 1.12–1.47Authors' conclusion
Clinical obesity is an independent risk factor for new-onset AF, with age- and sex-specific associations, while metabolic-targeted therapies were associated with attenuated obesity-associated new-onset AF risk.
Study context
- Population
- Individuals at first health examinations June 2006–October 2007 in Kailuan, free from atrial fibrillation (AF) at baseline1,343 developed AF
- Participants
- 98,730 individuals
- Exposure
- Clinical obesity and preclinical obesity vs no obesity
- Outcome
- New-onset AF
- Follow-up
- Median 16.97 years
Main finding
As reported in the abstract
Hazard ratio
1.29
95% CI 1.12–1.47
By group
No obesity
0.67 per 1000 person-years
Preclinical obesity
0.68 per 1000 person-years
Clinical obesity
1.25 per 1000 person-years
Clinical obesityvs No obesity
HR 1.29 (95% CI 1.12–1.47)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| New-onset AF, age <45 yearsClinical obesityvs No obesity | 2.34 (1.42–3.86) | |
| New-onset AF, age 45–<60 yearsClinical obesityvs No obesity | 1.40 (1.14–1.71) | |
| New-onset AF, menClinical obesityvs No obesity | 1.34 (1.16–1.55) | |
| New-onset AF, history of anti-hypertensive agent useClinical obesityvs No obesity | 0.98 (0.73–1.30) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Clinical Obesity and New‐Onset Atrial Fibrillation: A Population‐Based Cohort Study From the Kailuan Cohort. Diabetes Obes Metab. Published 21 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →